DE4308374C2 - Verwendung einer Organogermanium-Verbindung zur Unterdrückung bzw. Unterbrechung der Maillard-Reaktion - Google Patents

Verwendung einer Organogermanium-Verbindung zur Unterdrückung bzw. Unterbrechung der Maillard-Reaktion

Info

Publication number
DE4308374C2
DE4308374C2 DE4308374A DE4308374A DE4308374C2 DE 4308374 C2 DE4308374 C2 DE 4308374C2 DE 4308374 A DE4308374 A DE 4308374A DE 4308374 A DE4308374 A DE 4308374A DE 4308374 C2 DE4308374 C2 DE 4308374C2
Authority
DE
Germany
Prior art keywords
compound
organogermanium
group
maillard reaction
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE4308374A
Other languages
German (de)
English (en)
Other versions
DE4308374A1 (de
Inventor
Norihiro Kakimoto
Kunie Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asai Germanium Research Institute
Original Assignee
Asai Germanium Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asai Germanium Research Institute filed Critical Asai Germanium Research Institute
Publication of DE4308374A1 publication Critical patent/DE4308374A1/de
Application granted granted Critical
Publication of DE4308374C2 publication Critical patent/DE4308374C2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/30—Germanium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE4308374A 1992-03-16 1993-03-16 Verwendung einer Organogermanium-Verbindung zur Unterdrückung bzw. Unterbrechung der Maillard-Reaktion Expired - Fee Related DE4308374C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4091685A JPH05255130A (ja) 1992-03-16 1992-03-16 メイラード反応抑制改善剤

Publications (2)

Publication Number Publication Date
DE4308374A1 DE4308374A1 (de) 1993-10-07
DE4308374C2 true DE4308374C2 (de) 2002-01-03

Family

ID=14033361

Family Applications (1)

Application Number Title Priority Date Filing Date
DE4308374A Expired - Fee Related DE4308374C2 (de) 1992-03-16 1993-03-16 Verwendung einer Organogermanium-Verbindung zur Unterdrückung bzw. Unterbrechung der Maillard-Reaktion

Country Status (11)

Country Link
US (1) US5352815A (enExample)
JP (1) JPH05255130A (enExample)
KR (1) KR100245571B1 (enExample)
AU (1) AU659589B2 (enExample)
CA (1) CA2091651C (enExample)
CH (1) CH685876A5 (enExample)
DE (1) DE4308374C2 (enExample)
FR (1) FR2689763B1 (enExample)
GB (1) GB2265547B (enExample)
IT (1) IT1271438B (enExample)
TW (1) TW278036B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1143432A (ja) * 1997-07-25 1999-02-16 Biremo Sci:Kk 脳の老化抑制及び治療剤
CA2339879C (en) 1998-08-24 2011-11-15 Toshio Miyata Carbonyl-stress improving agent and peritoneal dialysate

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2190835A (en) * 1984-12-18 1987-12-02 Asai Germanium Res Inst Resistance imparting agent for cold syndrome
DE3928032A1 (de) * 1988-08-29 1990-03-01 Asai Germanium Res Inst Organogermaniumverbindungen und verfahren zu ihrer erzeugung
US4973553A (en) * 1987-09-09 1990-11-27 Asai Germanium Research Institute Salt or organogermanium compound and medicine containing the same
DE3720151C2 (enExample) * 1986-06-18 1990-12-06 Asai Germanium Research Institute, Tokio/Tokyo, Jp
DE3840744C2 (de) * 1987-12-07 1994-09-08 Asai Germanium Res Inst Aktivator für Osteoblasten

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA970277A (en) * 1972-05-25 1975-07-01 Kazuhiko Asai Organo germanium sesquioxide composition for treating hypertension or hypotonia
JPS5632485A (en) * 1979-08-24 1981-04-01 Pola Chem Ind Inc Preparation of organogermanium compound
DE3212817A1 (de) * 1982-04-06 1983-10-13 Sanum-Kehlbeck GmbH & Co KG, 2812 Hoya Pharmazeutisch wirksame organische germaniumverbindungen und verfahren zu deren herstellung
JPS601317B2 (ja) * 1982-08-23 1985-01-14 紀博 柿本 親水性及び親油性を併せ有する有機ゲルマニウム化合物
JPS6041472A (ja) * 1983-08-16 1985-03-05 Refuorumu Syst Kk 美容・健康飲料
JPS60226592A (ja) * 1984-04-25 1985-11-11 Asai Gerumaniumu Kenkyusho:Kk 抗酸化剤
CA1314210C (en) * 1987-10-29 1993-03-09 Norihiro Kakimoto Agent for improving reduced functions of organs caused by inhibited blood circulation
JP2698870B2 (ja) * 1987-10-29 1998-01-19 株式会社浅井ゲルマニウム研究所 シクロスポリンの投与による腎毒性の軽減剤
US5008416A (en) * 1989-06-20 1991-04-16 Sanwa Kagaku Kenkyusho Co., Ltd. Organogermanium compound, process for the preparation of same as well as use thereof
AU635045B2 (en) * 1989-07-20 1993-03-11 Asai Germanium Research Institute Co., Ltd Agent for preventing and treating opacity of lens
JPH03251526A (ja) * 1990-02-28 1991-11-11 Sanwa Kagaku Kenkyusho Co Ltd 糖尿病依存型自己免疫疾患治療、予防用薬剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2190835A (en) * 1984-12-18 1987-12-02 Asai Germanium Res Inst Resistance imparting agent for cold syndrome
US4898882A (en) * 1984-12-18 1990-02-06 Asai Germanium Research Institute Resistance imparting agent for cold syndrome of low pulmonary function patients
DE3720151C2 (enExample) * 1986-06-18 1990-12-06 Asai Germanium Research Institute, Tokio/Tokyo, Jp
US4973553A (en) * 1987-09-09 1990-11-27 Asai Germanium Research Institute Salt or organogermanium compound and medicine containing the same
DE3840744C2 (de) * 1987-12-07 1994-09-08 Asai Germanium Res Inst Aktivator für Osteoblasten
DE3928032A1 (de) * 1988-08-29 1990-03-01 Asai Germanium Res Inst Organogermaniumverbindungen und verfahren zu ihrer erzeugung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA 114:24071 X *

Also Published As

Publication number Publication date
TW278036B (enExample) 1996-06-11
GB2265547A (en) 1993-10-06
AU659589B2 (en) 1995-05-18
US5352815A (en) 1994-10-04
FR2689763A1 (fr) 1993-10-15
CH685876A5 (fr) 1995-10-31
FR2689763B1 (fr) 1995-04-28
JPH05255130A (ja) 1993-10-05
DE4308374A1 (de) 1993-10-07
ITMI930491A1 (it) 1994-09-15
KR100245571B1 (ko) 2000-03-02
ITMI930491A0 (it) 1993-03-15
CA2091651C (en) 2003-09-23
GB9305309D0 (en) 1993-05-05
AU3511893A (en) 1993-09-23
IT1271438B (it) 1997-05-28
CA2091651A1 (en) 1993-09-17
KR930019210A (ko) 1993-10-18
GB2265547B (en) 1996-07-31

Similar Documents

Publication Publication Date Title
DE3650080T2 (de) Verfahren und Mittel zur Hemmung des Proteinveraltens.
DE69012268T2 (de) Mittel zur Hemmung der alpha-Amylase Aktivität.
DE69624699T2 (de) Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
DE69830512T2 (de) Medikament für neurodegenerative Erkrankungen
DE69121561T2 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69113938T2 (de) Zusammensetzungen von Maillard-Reaktion inhibitoren.
DE69829763T2 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69030616T2 (de) Pharmazeutische Zusammensetzungen zur Hemmung der Maillardreaktion
DE3137125C2 (enExample)
DE3540632A1 (de) Immun-regulator
DE3883606T2 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE69530570T2 (de) Verfahren zur behandlung von stoehrungen des menschlichen oder tierischen koerpers durch verabreichung von aminosaeuren
DE2913211A1 (de) 2-(2-thenoylthio)propionylglycin, verfahren zu seiner herstellung und es enthaltende pharmazeutische mittel
DE3641495A1 (de) Mittel zum hemmen der entwicklung der pathologischen trunksucht
DE68915269T2 (de) Polyvalentes entzündungshemmendes mittel.
DE69825981T2 (de) 4,5-dihydroxy-2-cyclopenten-1-on für die Behandlung von Diabetes Mellitus
DE69708109T2 (de) Verfahren und zusammensetzungen zur steigerung der anaerobe leistungsfähigkeit in geweben
DE60220799T2 (de) Hypoglykämisches mittel
DE4308374A1 (de) Mittel zum Unterdrücken und Unterbrechen der Maillard-Reaktion
DE2630757A1 (de) L-pyroglutamyl-l-prolinamid, verfahren zu seiner herstellung und seine verwendung
DE3634496C2 (de) Glukosylmoranolinderivate und ihre Herstellung
DE69017825T2 (de) Heilverfahren von Lebererkrankungen mit Verwendung von Pyrrol-Chinolin-Chinone-Triester und neue Pyrrol-Chinolin-Chinone-Triester.
DE60114724T2 (de) Blutflussverbesserer und Mittel zur Vorbeugung oder Heilung von Thrombose
DE2625053C3 (de) Arzneimittel zur Kontrolle von Leberkrankheiten
DE69328945T2 (de) Pyridiniumderivate

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20121002